Identification of a three-miRNA signature as a blood-borne diagnostic marker for early diagnosis of lung adenocarcinoma.

Abstract

BACKGROUND:

The subtypes of NSCLC have unique characteristics of pathogenic mechanism and responses to targeted therapies. Thus, non-invasive markers for diagnosis of different subtypes of NSCLC at early stage are needed.

RESULTS:

Based on the results from the screening and validation process, 3 miRNAs (miR-532, miR-628-3p and miR-425-3p) were found to display significantly different expression levels in early-stage lung adenocarcinoma, as compared to those in healthy controls. ROC analysis showed that the miRNA-based biomarker could distinguish lung adenocarcinoma from healthy controls with high AUC (0.974), sensitivity (91.5%), and specificity (97.8%). Importantly, these three miRNAs could also distinguish lung adenocarcinoma from lung benigh diseases and other subtypes of lung cancer.

METHODS:

Two hundreds and one early-stage lung adenocarcinoma cases and one hundreds seventy eight age- and sex-matched healthy controls were recruited to this study. We screened the differentially expressed plasma miRNAs using TaqMan Low Density Arrays (TLDA) followed by three-phase qRT-PCR validation. A risk score model was established to evaluate the diagnostic value of the plasma miRNA profiling system.

CONCLUSIONS:

Taken together, these findings suggest that the 3 miRNA-based biomarker might serve as a novel non-invasive approach for diagnosis of early-stage lung adenocarcinoma.

• Authors: Yang Wang, Hua Zhao, Xujie Gao, Feng Wei, Xinwei Zhang, Yanjun Su, Changli Wang, Hui Li, Xiubao Ren
• Journal: Oncotarget (Oncotarget) Vol. 7 Issue 18 Pg. 26070-86 (May 03 2016) ISSN: 1949-2553 [Electronic] United States
• PMID: 27036025 (Publication Type: Journal Article)

Chemical References

• Biomarkers, Tumor
• MicroRNAs

Topics

• Adenocarcinoma (blood, diagnosis, genetics)
• Adult
• Aged
• Aged, 80 and over
• Biomarkers, Tumor (blood, genetics)
• Case-Control Studies
• Early Detection of Cancer
• Female
• Follow-Up Studies
• Humans
• Lung Neoplasms (blood, diagnosis, genetics)
• Male
• MicroRNAs (blood, genetics)
• Middle Aged
• Prognosis
• Survival Rate
• Young Adult